Zydus Cadila signs agreement with Gilead Sciences to manufacture, market Remdesivir

13 Jun 2020 Evaluate

Zydus Cadila has signed a non-exclusive licensing agreement with Gilead Sciences Inc., for the manufacturing and distribution of Remdesivir, the investigational drug, which has been issued an Emergency Use Authorization by the U.S. Food and Drug Administration (USFDA) to treat patients suffering from severe symptoms of Novel Coronavirus. The company has been supporting the fight against COVID 19 with therapeutics, vaccines and diagnostics.

As part of the non-exclusive agreement, the company will receive the manufacturing know-how from Gilead Sciences Inc., to manufacture the API for Remdesivir and the finished product and market it in 127 countries, including India. Under the agreement, the license is royalty free until another pharmaceutical product or vaccine is approved for the treatment or prevention of COVID 19 by the USFDA or EMA or the WHO announcing the end of the public health emergency. Zydus will leverage its ability to scale up production to reach patients across India and across the 127 countries in Gilead’s Global Patient Solution region.

Cadila Healthcare is an India-based pharmaceutical company. The company's subsidiaries include Zydus Wellness, Liva Pharmaceuticals, Biochem Pharmaceutical Industries, Zydus Technologies, German Remedies, Dialforhealth India, Dialforhealth Unity and Dialforhealth Greencross, among others.

Zydus Lifesciences Share Price

962.75 14.85 (1.57%)
29-Apr-2024 11:04 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1520.90
Dr. Reddys Lab 6261.70
Cipla 1397.95
Zydus Lifesciences 962.75
Lupin 1633.50
View more..
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt.Ltd.